[{"id":"e0be9b49-8cbc-4688-a452-7aaedd1a1b20","acronym":"","url":"https://clinicaltrials.gov/study/NCT05228015","created_at":"2022-02-12T17:47:53.327Z","updated_at":"2024-07-02T16:35:09.961Z","phase":"Phase 1","brief_title":"Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT05228015","lead_sponsor":"Ikena Oncology","biomarkers":" YAP1 • TFE3 • CAMTA1 • TAFAZZIN","pipe":" | ","alterations":" TFE3 fusion","tags":["YAP1 • TFE3 • CAMTA1 • TAFAZZIN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TFE3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • IK-930"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 01/07/2022","start_date":" 01/07/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-04-12"},{"id":"342a7365-a0cb-40b4-a3bd-26c53a69ba15","acronym":"INHERIT","url":"https://clinicaltrials.gov/study/NCT05587439","created_at":"2022-10-20T14:11:35.154Z","updated_at":"2024-07-02T16:35:18.802Z","phase":"","brief_title":"Investigating Hereditary Risk In Thoracic Cancers (INHERIT)","source_id_and_acronym":"NCT05587439 - INHERIT","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" EGFR • HER-2 • YAP1","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • MET mutation • EGFR R776H","tags":["EGFR • HER-2 • YAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • MET mutation • EGFR R776H"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-02-19"},{"id":"ef5f595b-9e34-4513-9b8d-50b1aa6a34da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03176381","created_at":"2021-01-18T15:39:48.196Z","updated_at":"2024-07-02T16:35:29.387Z","phase":"","brief_title":"Tissue Predictors of Abiraterone Benefit","source_id_and_acronym":"NCT03176381","lead_sponsor":"Tianjin Medical University Second Hospital","biomarkers":" YAP1 • PCNA","pipe":" | ","alterations":" YAP1 positive • PCNA expression","tags":["YAP1 • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YAP1 positive • PCNA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 05/05/2017","start_date":" 05/05/2017","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2023-11-14"},{"id":"55ac3e56-b4fa-49c6-a13c-2a74dc16678c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04659096","created_at":"2021-01-19T20:42:10.948Z","updated_at":"2024-07-02T16:35:58.747Z","phase":"Phase 1","brief_title":"A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors","source_id_and_acronym":"NCT04659096","lead_sponsor":"Ionis Pharmaceuticals, Inc.","biomarkers":" YAP1","pipe":"","alterations":" ","tags":["YAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ION537"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 01/05/2021","start_date":" 01/05/2021","primary_txt":" Primary completion: 10/19/2022","primary_completion_date":" 10/19/2022","study_txt":" Completion: 10/19/2022","study_completion_date":" 10/19/2022","last_update_posted":"2022-12-21"},{"id":"c1c9f95c-3181-44bf-bb08-046e38a9eb11","acronym":"CTC_ctDNA","url":"https://clinicaltrials.gov/study/NCT05208372","created_at":"2022-01-26T12:53:35.960Z","updated_at":"2024-07-02T16:36:17.977Z","phase":"","brief_title":"Detection of CTC and ctDNA in the Diagnosis of Metastasis in Gastric Cancer","source_id_and_acronym":"NCT05208372 - CTC_ctDNA","lead_sponsor":"First Hospital of China Medical University","biomarkers":" YAP1 • DDIT4 • LAMC1","pipe":"","alterations":" ","tags":["YAP1 • DDIT4 • LAMC1"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 01/31/2024","study_completion_date":" 01/31/2024","last_update_posted":"2022-01-26"}]